OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
🇺🇸United States
A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia
A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2015-09-21
- Target Recruit Count
- 631
- Registration Number
- NCT02435836
Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2017-02-15
- Target Recruit Count
- 40
- Registration Number
- NCT02411695
Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)
Phase 4
Completed
- Conditions
- Device Latency
- Interventions
- Device: MIND1 System
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2018-08-03
- Target Recruit Count
- 30
- Registration Number
- NCT02404532
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2019-11-27
- Target Recruit Count
- 1803
- Registration Number
- NCT02251275
Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole
Phase 2
Completed
- Conditions
- Nervous System DiseasesMental DisorderSchizophrenia
- Interventions
- Device: MIND1 System
- First Posted Date
- 2014-08-18
- Last Posted Date
- 2018-08-15
- Target Recruit Count
- 67
- Registration Number
- NCT02219009
Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability
Phase 3
Withdrawn
- Conditions
- Major Depressive Disorder and Irritability
- Interventions
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
Phase 3
Completed
- Conditions
- Mental DisordersDepressionDepressive DisorderDepressive Disorder, MajorMood Disorders
- Interventions
- Drug: Placebo + ADT
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2018-08-21
- Target Recruit Count
- 837
- Registration Number
- NCT02196506
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2018-11-08
- Target Recruit Count
- 38
- Registration Number
- NCT02194933
- Locations
- 🇺🇸
University of California at Irvine Medical Center, Orange, California, United States
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
Completed
- Conditions
- Alzheimer's TypeMental DisorderNervous System DiseasesAgitation Associated With Alzheimer's Disease
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2018-04-30
- Target Recruit Count
- 450
- Registration Number
- NCT02192554
© Copyright 2025. All Rights Reserved by MedPath